Monopar Therapeutics MNPR
NASDAQ MNPR
$118.15 -0.40 (-0.34%)
As of: Sep 4, 2026 · 2:18 PM EDT

Monopar Therapeutics (MNPR) Total Debt (2020)

Monopar Therapeutics (MNPR) posted Total Debt of $122400.0 for Q3 2020, little changed sequentially from $122400.0 in Q2 2020.

Analysis

Monopar Therapeutics (MNPR) Total Debt (2020) Analysis & Trends

Monopar Therapeutics has reported Total Debt for 1 years, with the latest figure at $122400.0 in Q3 2020.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 138.87 Bn 131.01 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.57 Bn 77.57 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn -
4 Moderna 58.19 Bn 53.05 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.07 Bn 44.07 Bn - -
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn 1.07 Bn
7 Alnylam Pharmaceuticals 35.38 Bn 32.07 Bn 992.69 Mn -
8 Royalty Pharma 28.42 Bn 27.58 Bn - 9.34 Bn
9 Insmed 27.41 Bn 26.25 Bn 358.27 Mn 546.77 Mn
10 Monopar Therapeutics 1.01 Bn 956.53 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 122,400.00
Jun 30, 2020 122,400.00